497 related articles for article (PubMed ID: 31265130)
1. Parkinson's disease biomarkers based on α-synuclein.
Fayyad M; Salim S; Majbour N; Erskine D; Stoops E; Mollenhauer B; El-Agnaf OMA
J Neurochem; 2019 Sep; 150(5):626-636. PubMed ID: 31265130
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic biomarkers for Parkinson's disease: focus on α-synuclein in cerebrospinal fluid.
Kalia LV
Parkinsonism Relat Disord; 2019 Feb; 59():21-25. PubMed ID: 30466800
[TBL] [Abstract][Full Text] [Related]
3. α-synuclein imaging: a critical need for Parkinson's disease research.
Eberling JL; Dave KD; Frasier MA
J Parkinsons Dis; 2013; 3(4):565-7. PubMed ID: 24192754
[TBL] [Abstract][Full Text] [Related]
4. Alpha-Synuclein as a Biomarker for Parkinson's Disease.
Atik A; Stewart T; Zhang J
Brain Pathol; 2016 May; 26(3):410-8. PubMed ID: 26940058
[TBL] [Abstract][Full Text] [Related]
5. Alpha-synuclein in peripheral tissues and body fluids as a biomarker for Parkinson's disease - a systematic review.
Malek N; Swallow D; Grosset KA; Anichtchik O; Spillantini M; Grosset DG
Acta Neurol Scand; 2014 Aug; 130(2):59-72. PubMed ID: 24702516
[TBL] [Abstract][Full Text] [Related]
6. Feasibility and Safety of Multicenter Tissue and Biofluid Sampling for α-Synuclein in Parkinson's Disease: The Systemic Synuclein Sampling Study (S4).
Chahine LM; Beach TG; Seedorff N; Caspell-Garcia C; Coffey CS; Brumm M; Adler CH; Serrano GE; Linder C; Mosovsky S; Foroud T; Riss H; Ecklund D; Seibyl J; Jennings D; Arnedo V; Riley L; Dave KD; Mollenhauer B;
J Parkinsons Dis; 2018; 8(4):517-527. PubMed ID: 30248065
[TBL] [Abstract][Full Text] [Related]
7. Dermal phospho-alpha-synuclein deposits confirm REM sleep behaviour disorder as prodromal Parkinson's disease.
Doppler K; Jentschke HM; Schulmeyer L; Vadasz D; Janzen A; Luster M; Höffken H; Mayer G; Brumberg J; Booij J; Musacchio T; Klebe S; Sittig-Wiegand E; Volkmann J; Sommer C; Oertel WH
Acta Neuropathol; 2017 Apr; 133(4):535-545. PubMed ID: 28180961
[TBL] [Abstract][Full Text] [Related]
8. Can we use peripheral tissue biopsies to diagnose Parkinson's disease? A review of the literature.
Schneider SA; Boettner M; Alexoudi A; Zorenkov D; Deuschl G; Wedel T
Eur J Neurol; 2016 Feb; 23(2):247-61. PubMed ID: 26100920
[TBL] [Abstract][Full Text] [Related]
9. Quantification of Alpha-Synuclein in Biological Fluids by Electrochemiluminescence-Based Detection.
Kruse N; Mollenhauer B
Methods Mol Biol; 2019; 1948():59-68. PubMed ID: 30771170
[TBL] [Abstract][Full Text] [Related]
10. Brain alpha-synuclein accumulation in multiple system atrophy, Parkinson's disease and progressive supranuclear palsy: a comparative investigation.
Tong J; Wong H; Guttman M; Ang LC; Forno LS; Shimadzu M; Rajput AH; Muenter MD; Kish SJ; Hornykiewicz O; Furukawa Y
Brain; 2010 Jan; 133(Pt 1):172-88. PubMed ID: 19903734
[TBL] [Abstract][Full Text] [Related]
11. Post-translational modification of α-synuclein in Parkinson's disease.
Barrett PJ; Timothy Greenamyre J
Brain Res; 2015 Dec; 1628(Pt B):247-253. PubMed ID: 26080075
[TBL] [Abstract][Full Text] [Related]
12. Abnormal Salivary Total and Oligomeric Alpha-Synuclein in Parkinson's Disease.
Vivacqua G; Latorre A; Suppa A; Nardi M; Pietracupa S; Mancinelli R; Fabbrini G; Colosimo C; Gaudio E; Berardelli A
PLoS One; 2016; 11(3):e0151156. PubMed ID: 27011009
[TBL] [Abstract][Full Text] [Related]
13. Cerebrospinal fluid Tau/α-synuclein ratio in Parkinson's disease and degenerative dementias.
Parnetti L; Chiasserini D; Bellomo G; Giannandrea D; De Carlo C; Qureshi MM; Ardah MT; Varghese S; Bonanni L; Borroni B; Tambasco N; Eusebi P; Rossi A; Onofrj M; Padovani A; Calabresi P; El-Agnaf O
Mov Disord; 2011 Jul; 26(8):1428-35. PubMed ID: 21469206
[TBL] [Abstract][Full Text] [Related]
14. Longitudinal changes in CSF alpha-synuclein species reflect Parkinson's disease progression.
Majbour NK; Vaikath NN; Eusebi P; Chiasserini D; Ardah M; Varghese S; Haque ME; Tokuda T; Auinger P; Calabresi P; Parnetti L; El-Agnaf OM
Mov Disord; 2016 Oct; 31(10):1535-1542. PubMed ID: 27548849
[TBL] [Abstract][Full Text] [Related]
15. How should we be using biomarkers in trials of disease modification in Parkinson's disease?
Vijiaratnam N; Foltynie T
Brain; 2023 Dec; 146(12):4845-4869. PubMed ID: 37536279
[TBL] [Abstract][Full Text] [Related]
16. α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study.
Mollenhauer B; Locascio JJ; Schulz-Schaeffer W; Sixel-Döring F; Trenkwalder C; Schlossmacher MG
Lancet Neurol; 2011 Mar; 10(3):230-40. PubMed ID: 21317042
[TBL] [Abstract][Full Text] [Related]
17. Molecular imaging insights into neurodegeneration: focus on α-synuclein radiotracers.
Shah M; Seibyl J; Cartier A; Bhatt R; Catafau AM
J Nucl Med; 2014 Sep; 55(9):1397-400. PubMed ID: 25091474
[TBL] [Abstract][Full Text] [Related]
18. Oligomeric α-synuclein and β-amyloid variants as potential biomarkers for Parkinson's and Alzheimer's diseases.
Williams SM; Schulz P; Sierks MR
Eur J Neurosci; 2016 Jan; 43(1):3-16. PubMed ID: 26332448
[TBL] [Abstract][Full Text] [Related]
19. Pursuing Multiple Biomarkers for Early Idiopathic Parkinson's Disease Diagnosis.
Gopar-Cuevas Y; Duarte-Jurado AP; Diaz-Perez RN; Saucedo-Cardenas O; Loera-Arias MJ; Montes-de-Oca-Luna R; Rodriguez-Rocha H; Garcia-Garcia A
Mol Neurobiol; 2021 Nov; 58(11):5517-5532. PubMed ID: 34350555
[TBL] [Abstract][Full Text] [Related]
20. Alpha-synuclein in peripheral body fluid as a biomarker for Parkinson's disease.
Shu H; Zhang P; Gu L
Acta Neurol Belg; 2024 Jun; 124(3):831-842. PubMed ID: 38170418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
